Gilead Sciences, Inc. notes it was an early adopter when it comes to trial diversity because of its historic focus on HIV. But its development of Veklury (remdesivir) brought it into the spotlight when The New England Journal of Medicine published an article in August 2020 highlighting disproportionate enrollment of white participants in the National Institutes of Health’s early trials of the COVID-19 antiviral. That article helped jumpstart the biopharma industry’s current focus on clinical trial diversity.
How Gilead Did Trial Diversity Before It Was Cool
Thanks in part to its HIV focus, Gilead was an early adopter when it came to emphasizing diversity in trials.
